SAN DIEGO, Nov. 17 /PRNewswire/ -- ActiveSight announced today that it has signed an agreement to provide structural biology services to Inpharmatica Ltd. The agreement focuses on co-crystallography by ActiveSight of certain Inpharmatica small molecules with a human drug target protein. The agreement includes upfront fees and payments for milestones.
"ActiveSight is delighted to augment Inpharmatica's unique drug discovery platform," stated Duncan McRee, Ph.D., President of ActiveSight.
ActiveSight was formed in 2003 to provide high-level structural biology services to advance clients' drug discovery efforts.
ActiveSight (TM), a division of Rigaku Americas Corporation, features a full range of protein crystallography services, as well as a Portfolio of "ready to go" drug targets for co-crystallography. The Portfolio includes the oncology targets Hsp90 and Aurora-A kinase; nuclear hormone receptor targets PPAR-delta and FXR, implicated in obesity; PDE-4 for asthma and inflammation; the hypertension target renin; the type-II diabetes target FBPase; and the anti-infective target bacterial gyrase.
ActiveSight also offers full gene-to-structure custom research services for client's targets, including X-ray data collection and fragment-based screening, featuring the Rigaku FR-E and ACTOR automation systems. For more information visit www.active-sight.com. ActiveSight(TM) is a trademark of Rigaku Americas Corporation.
CONTACT: Joy Silen of ActiveSight, +1-858-455-6870, ext. 105